75% of biopharma leaders expect partnering and M&A appetite to increase over the next 12 months, none expect a decline 69% expect access to capital to improve, yet 79% identify investor risk aversion as the biggest constraint on biotech investment 52% say US policy uncertainty has made Europe more attractive to build and partner in, […]
San Francisco, California – Yavne, Israel – July 14th, 2026 – Genopore, the next-generation proteomics company developing the first semiconductor based optical nanopore technology platform with AI/ML analysis for direct single protein molecule identification and digital quantification, today announced the appointment of life science leader Rey Mali as its new Chief Executive Officer, with immediate […]
Exceptional track record across multiple clinical development programs for depression, three of which have resulted in regulatory approvals Appointment strengthens confidence in clinical readiness and execution as the Company progresses toward first-in-human development Heidelberg, Germany – 2 June 2026 – FundaMental Pharma GmbH (or “the Company”), a preclinical-stage biopharmaceutical company focused on developing innovative, dual-acting N-methyl-D-aspartate […]
Advancing development of lead candidate BT-101, a potential disease-modifying treatment for Brittle Bone Disease Preparing for Phase III development following promising data showing reduced fractures in affected children Stockholm, Sweden, February 10, 2026 – BOOST Pharma (“BOOST” or the “Company), a clinical‑stage biopharmaceutical company developing novel, first‑in‑class off-the-shelf cell therapies for rare, debilitating pediatric skeletal […]
